| Size | Price | Stock | Qty |
|---|---|---|---|
| 100g |
|
||
| Other Sizes |
| Targets |
4-Bromo-2-methylbenzoic acid does not have a specific primary biological target, as it functions primarily as a synthetic intermediate. However, research indicates that the compound exhibits biological activity, including enzyme inhibition and antibacterial activity. It is a precursor for Na+/H+ antiporter inhibitors and anthranilic acids with antibacterial activity. Na+/H+ antiporters are membrane proteins involved in pH regulation and ion transport, and their inhibitors are being investigated for the treatment of cardiovascular diseases and cancer. Anthranilic acids are known to possess antibacterial activity, and derivatives of this compound are evaluated for their potential as antimicrobial agents. The compound's derivatives, such as hydrazides and pyrrolidines, are synthesized and evaluated for their biological activities.
|
|---|---|
| ln Vitro |
In vitro, 4-bromo-2-methylbenzoic acid is used in electrophilic substitution reactions for constructing complex aromatic systems. It is used in the synthesis of (2-methyl-5-(methylsulfonyl)benzoyl)guanidine derivatives. The compound is a building block used in the preparation of anthranilic acids possessing antibacterial activity. Derivatives of this compound, such as the corresponding hydrazide and pyrrolidines, are synthesized and evaluated for their potential antibacterial and antifungal activities. The compound is employed to study enzyme inhibition mechanisms, contributing to drug discovery efforts. In medicinal chemistry, it serves as a versatile building block for constructing biologically active molecules.
|
| ln Vivo |
In vivo activity is mediated through the derivatives of 4-bromo-2-methylbenzoic acid rather than the parent compound itself. For example, Na+/H+ antiporter inhibitors and anthranilic acids with antibacterial activity synthesized from this compound are evaluated in animal models. Antibacterial and antifungal derivatives are evaluated in animal models of infection. However, specific in vivo studies on the parent compound are limited, as it is a synthetic intermediate rather than a pharmacological agent.
|
| Enzyme Assay |
Cell-free assays involving 4-bromo-2-methylbenzoic acid are focused on its use as a chemical reagent. Standard protocols for carboxylate derivatization involve activating the carboxylic acid with coupling reagents such as EDC/HOBt, followed by reaction with amines to form amides. The reaction progress is monitored by TLC or HPLC. For enzyme inhibition studies, the compound or its derivatives are incubated with target enzymes in buffer solutions, and enzymatic activity is measured using appropriate substrates. The compound's reactivity can be studied using various analytical techniques, including NMR spectroscopy and mass spectrometry. Its use in the synthesis of anthranilic acids involves standard organic synthesis procedures.
|
| Cell Assay |
Cellular assays are not performed with the parent compound 4-bromo-2-methylbenzoic acid. Instead, its derivatives, such as anthranilic acids with antibacterial activity, are evaluated in cell-based systems. For antibacterial activity, derivatives are tested against bacterial cultures using standard broth microdilution methods to determine minimum inhibitory concentrations. For antifungal activity, derivatives are tested against fungal cultures. The parent compound itself is not used as a test article in cell-based experiments due to its role as a synthetic building block.
|
| Animal Protocol |
Animal studies are not conducted with the parent compound 4-bromo-2-methylbenzoic acid. Its derivatives, such as Na+/H+ antiporter inhibitors and antibacterial agents, are evaluated in animal models. For antibacterial agents, animal models of bacterial infection are used, and bacterial clearance and survival rates are assessed. For Na+/H+ antiporter inhibitors, animal models of cardiovascular diseases are used. The parent compound itself is not administered to animals.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for 4-bromo-2-methylbenzoic acid are not available. As a small polar molecule with a molecular weight of 215.04 g/mol, it is expected to have moderate bioavailability if administered, but it is not intended for therapeutic use. The compound is insoluble in water, which may affect its absorption and distribution. Comprehensive pharmacokinetic studies have not been performed, as the compound is not intended for systemic administration. For research purposes, the compound is typically handled as a neat chemical and not administered to living organisms for pharmacokinetic profiling.
|
| Toxicity/Toxicokinetics |
Toxicological data for 4-bromo-2-methylbenzoic acid are limited. The compound is insoluble in water and should be stored away from oxidizing agents. Standard safety precautions for handling carboxylic acids and halogenated compounds apply, including the use of personal protective equipment such as gloves and safety goggles. The compound should be handled in a well-ventilated area, and contact with skin and eyes should be avoided. In case of exposure, affected areas should be rinsed thoroughly with water. The compound is not classified as a carcinogen or mutagen based on available data, but comprehensive toxicological evaluation has not been performed. As with all research chemicals, it should be handled with care and used only in accordance with safety guidelines.
|
| Additional Infomation |
4-Bromo-2-methylbenzoic acid is a research chemical, not an approved drug. It has no clinical trial or marketing approval status for therapeutic use. The compound is a building block used in the preparation of anthranilic acids possessing antibacterial activity. It is employed to study enzyme inhibition mechanisms, contributing to drug discovery efforts. Derivatives of this compound, such as the corresponding hydrazide and pyrrolidines, are synthesized and evaluated for their potential antibacterial and antifungal activities. The compound is a precursor for Na+/H+ antiporter inhibitors and anthranilic acids with antibacterial activity. It is insoluble in water and should be stored away from oxidizing agents. It is supplied with a purity of ≥98% and is an important compound that can be used in the synthesis of other active compounds.
|
| Molecular Formula |
C8H7BRO2
|
|---|---|
| Molecular Weight |
215.04
|
| Exact Mass |
213.962
|
| CAS # |
68837-59-2
|
| PubChem CID |
99570
|
| Appearance |
Off-white to pink solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Boiling Point |
310.1±30.0 °C at 760 mmHg
|
| Melting Point |
180-184 °C
|
| Flash Point |
141.3±24.6 °C
|
| Vapour Pressure |
0.0±0.7 mmHg at 25°C
|
| Index of Refraction |
1.595
|
| LogP |
3.32
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
11
|
| Complexity |
158
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=CC(=CC=C1C(=O)O)Br
|
| InChi Key |
RVCJOGNLYVNRDN-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C8H7BrO2/c1-5-4-6(9)2-3-7(5)8(10)11/h2-4H,1H3,(H,10,11)
|
| Chemical Name |
4-bromo-2-methylbenzoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.6503 mL | 23.2515 mL | 46.5030 mL | |
| 5 mM | 0.9301 mL | 4.6503 mL | 9.3006 mL | |
| 10 mM | 0.4650 mL | 2.3251 mL | 4.6503 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
